The Quantellect read.As of Nov 19, 2026, 10 active firms cover Regenxbio Inc: 8 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $12.00 to $50.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $24.00 sits 230% above the current $7.28. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.06 next quarter toward $-3.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy880%
Neutral220%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.00
+229.9% upside
Average target across 10 active firms as of Nov 19, 2026 vs $7.28 current
Highest Target$50.00
Average Target$24.00
Lowest Target$12.00
Detailed analyst forecasts for RGNX
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 8 of 10 active firms rate RGNX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RGNX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.06
Range $-1.22 – $-0.78 · 3 analysts · -38% YoY
Next period, 3 analysts expect Regenxbio Inc to earn $-1.06 a share (range $-1.22 – $-0.78), versus $-1.72 a year earlier. Full-year consensus is $-3.58, growing to $-3.29 the year after.
REVENUE · NEXT QUARTER
$9.0M
Range $7.0M – $10.0M · 3 analysts · +41% YoY
Revenue is expected to reach $9.0M (range $7.0M – $10.0M), +40.8% year-over-year. Full-year consensus is $156.1M, rising to $198.5M next year.
Top analysts covering Regenxbio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RGNX.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$50.00+587.3% to target
Overall win rate
52%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Buy
$19.00+161.2% to target
Overall win rate
49%
+ Follow
#3
Paul Choi
Goldman Sachs · Rank #110
Neutral
$10.00+37.5% to target
Overall win rate
52%
+ Follow
#4
Graig Suvannavejh
Mizuho · Rank #239
Buy
$22.00+202.4% to target
Overall win rate
40%
+ Follow
#5
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$21.00+188.7% to target
Overall win rate
34%
+ Follow
RGNX stock forecast FAQ
What is RGNX's average 12-month price target?+
The 10 active firms with a live target average $24.00 for Regenxbio Inc over the next 12 months, ranging from a $50.00 high to a $12.00 low, as of Nov 19, 2026.
Is RGNX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RGNX?+
The Street-high target is $50.00 (Chardan Capital), and the Street-low is $12.00 (Barclays). The average of all 10 active-firm targets is $24.00.
How many active Wall Street firms cover RGNX?+
10 active firms have a recognized rating on Regenxbio Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RGNX?+
Among analysts who currently cover RGNX, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $50.00 target.
What is Regenxbio Inc's projected EPS for next quarter?+
The consensus estimate is $-1.06 per share (range $-1.22 – $-0.78) across 3 analysts. Full-year EPS is projected at $-3.58, rising to $-3.29 the following year.
How much revenue is Regenxbio Inc expected to report next quarter?+
Consensus revenue is $9.0M (range $7.0M – $10.0M). Full-year revenue is projected at $156.1M, growing to $198.5M next year.
Have analysts been upgrading or downgrading RGNX lately?+
As of Nov 19, 2026, 8 of 10 active firms rate RGNX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RGNX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.